TABLE 1.
Patient and DCIS characteristics by age at diagnosis (n = 2037, univariate analyses)a
| Characteristic | Patient age
|
P
|
||||
|---|---|---|---|---|---|---|
| <40 Years | 40–70 Years | >70 Years | All groups | <40 versus ≥40 Years | ≤70 versus >70 Years | |
| No. of patients | 132 (6.5) | 1690 (83.0) | 215 (10.5) | |||
| Race | ||||||
| White | 91 (68.9) | 1222 (72.3) | 170 (79.1) | |||
| African American | 20 (15.2) | 179 (10.6) | 33 (15.3) | |||
| Hispanic | 12 (9.1) | 166 (9.8) | 7 (3.3) | |||
| Asian/Pacific Islander | 8 (6.1) | 100 (5.9) | 5 (2.3) | |||
| Other | 1 (0.7) | 23 (1.4) | 0 (0) | 0.002 | 0.641 | 0.004 |
| Age | ||||||
| Median (range) | 37 (18–39) | 54 (40–70) | 74 (71–89) | <0.001 | <0.001 | <0.001b |
| <21 years | 2 (0.1) | |||||
| 21–30 years | 10 (0.5) | |||||
| 31–39 years | 120 (5.9) | |||||
| Exactly 40 years | 37 (1.8) | |||||
| 41–50 years | 573 (28.1) | |||||
| 51–60 years | 658 (32.3) | |||||
| 61–70 years | 422 (20.7) | |||||
| >70 years | 215 (10.6) | |||||
| Any family history of breast and/or ovarian cancer | 85 (64.4) | 794 (47.0) | 84 (39.1) | <0.001 | <0.001 | 0.011 |
| First-degree family history of breast and/or ovarian cancer | 26 (19.7) | 346 (20.5) | 62 (28.8) | 0.017 | 0.641 | 0.004 |
| Presence of bilateral breast cancer at diagnosis | 9 (6.8) | 121 (7.2) | 17 (7.9) | 0.908 | 0.855 | 0.679 |
| Initial presenting signsc | ||||||
| Clinical | 74 (56.1) | 233 (13.9) | 32 (15.0) | |||
| Radiologic | 58 (43.9) | 1446 (86.1) | 181 (85.0) | 0.001 | 0.001 | 0.476 |
| Dimension | ||||||
| Largest recorded mammographic dimension, median (range)d | 2.4 (0.2–15) | 2.0 (0.01–20) | 2.2 (0.3–11.3) | 0.737 | 0.537 | 0.670b |
| Largest recorded pathologic dimension, median (range)e | 1.2 (0.1–19) | 1.3 (0.01–18) | 1.2 (0.09–16) | 0.642 | 0.469 | 0.593b |
| Disease | ||||||
| Multicentricf | 29 (29.3) | 215 (17.7) | 21 (13.3) | 0.004 | 0.003 | 0.100 |
| Multifocalg | 28 (30.1) | 204 (17.5) | 20 (13.0) | 0.002 | 0.001 | 0.098 |
| Nuclear gradeh | ||||||
| I | 6 (4.7) | 162 (9.8) | 26 (12.2) | |||
| II or III | 121 (95.3) | 1491 (90.2) | 188 (87.9) | 0.080 | 0.049 | 0.206 |
| Necrosis present | 59 (44.7) | 630 (37.3) | 79 (36.7) | 0.227 | 0.086 | 0.759 |
| ER statusi | ||||||
| Positive | 64 (88.9) | 820 (80.7) | 100 (76.3) | |||
| Negative | 8 (11.1) | 196 (19.3) | 31 (23.7) | 0.095 | 0.070 | 0.178 |
| Surgery | ||||||
| BCS | 56 (42.4) | 1015 (60.1) | 145 (67.4) | |||
| Mastectomy | 76 (57.6) | 675 (39.9) | 70 (32.6) | 0.001 | 0.001 | 0.014 |
| Immediate breast reconstruction (in patients who underwent mastectomy) | 64 (82.1) | 449 (66.4) | 11 (15.7) | <0.001 | <0.001 | <0.001 |
| Contralateral prophylactic mastectomy | 28 (21.2) | 118 (7.0) | 4 (1.9) | <0.001 | <0.001 | 0.001 |
| Chemotherapy | ||||||
| Adjuvant tamoxifen (in all patients) | 38 (28.8) | 630 (37.3) | 59 (27.4) | 0.004 | 0.087 | 0.008 |
| Adjuvant tamoxifen (in patients who underwent BCS) | 20 (35.7) | 462 (45.5) | 39 (26.9) | <0.001 | 0.270 | <0.001 |
| Adjuvant tamoxifen (in patients who underwent mastectomy) | 18 (23.7) | 168 (24.9) | 20 (28.6) | 0.761 | 0.766 | 0.483 |
| Adjuvant radiotherapy (in patients who underwent BCS) | 46 (82.1) | 828 (81.6) | 103 (71.0) | 0.011 | 0.729 | 0.003 |
| Adjuvant tamoxifen and radiotherapy (in patients who underwent BCS) | 19 (67.9) | 408 (75.4) | 29 (47.5) | <0.001 | 0.584 | <0.001 |
DCIS ductal carcinoma-in-situ, ER estrogen receptor, BCS breast-conserving surgery
a
P values are from the chi-square test unless otherwise indicated
b
Calculated by the Kruskal-Wallis test
c
Initial presentations were not available for 13 patients
d
Largest mammographic dimensions recorded in 890 patients
e
Largest pathological sizes recorded in 1534 patients
f
Multicentric disease status recorded in 1469 patients
g
Multifocal diseased status recorded in 1416 patients
h
Nuclear grades were not available for 43 patients
i
ER status was determined in 1219 patients